 Imaging to assess response will be obtained at the end of cycle 1 - 1 week, at the end of cycle 3 - 2 weeks and after every three cycles thereafter - 2 weeks. A cycle will consist of 28 days - 3 days and MEK162 will be given continuously. Patients deriving benefit may continue therapy beyond study completion but all protocol specific evaluations other than survival or progression will conclude after one year. All patients will be followed with progression as the end point. 